XML 38 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Condensed Statements of Stockholders’ Equity (Unaudited) - USD ($)
Series A
Preferred Stock
Preferred Stock
Common Shares
Common Stock
Share Subscription Receivable
Additional Paid-in- Capital
Accumulated Other Comprehensive Income/ (Loss)
Accumulated Deficit
Total Mawson Stockholders’ Equity
Non- controlling interest
Total
Balance at Dec. 31, 2019   $ 9,093,549 $ (217,003) $ (1,447,092) $ 7,429,454 $ 7,429,454
Balance (in Shares) at Dec. 31, 2019   6,578,672              
Issuance of common stock, net of offering costs     $ 1,738,508     1,738,508 1,738,508
Issuance of common stock, net of offering costs (in Shares)     268,793                
Issuance of common stock, net of offering costs (@A$8.75)           1,768,250     1,768,250   1,768,250
Issuance of common stock, net of offering costs (@A$8.75) (in Shares)     331,368                
Comprehensive gain / (loss)           3,401,739 227,899 (6,131,591) (5,903,692)   (5,903,692)
Balance at Sep. 30, 2020 $ 10,832,057 1,768,250 10,896 (7,578,683) 5,032,520 5,032,520
Balance (in Shares) at Sep. 30, 2020 7,178,833              
Balance at Jun. 30, 2020   $ 10,832,057 (308,605) (4,030,443) 6,493,009 6,493,009
Balance (in Shares) at Jun. 30, 2020     6,847,465                
Issuance of common stock (@A$8.75)       1,768,250 1,768,250 1,768,250
Issuance of common stock (@A$8.75) (in Shares)     331,368              
Comprehensive gain / (loss)             319,501 (3,548,240) 3,228,739   (3,228,739)
Balance at Sep. 30, 2020 $ 10,832,057 1,768,250 10,896 (7,578,683) 5,032,520 5,032,520
Balance (in Shares) at Sep. 30, 2020 7,178,833              
Balance at Dec. 31, 2020   $ 7,539,275 (16,690) 15,298,926 (1,341,826) (6,348,465) 15,131,220 (27,066) 15,104,154
Balance (in Shares) at Dec. 31, 2020                
Exchange of stock and Reverse recapitalisation of Wize Pharma Inc     $ (7,539,275) $ 511,882 (5,436,541)   (12,463,934) (12,463,934)
Exchange of stock and Reverse recapitalisation of Wize Pharma Inc (in Shares)   178   51,188,168              
Issuance of common stock, net of offer costs, PIPE transaction     $ 25,000 2,975,000   3,000,000 3,000,000
Issuance of common stock, net of offer costs, PIPE transaction (in Shares)     2,500,000              
Issuance of convertible notes, net of offer costs     20,301,427   20,301,427 20,301,427
Issuance of convertible notes, net of offer costs (in Shares)                  
Issuance of warrants           6,881,676     6,881,676   6,881,676
Issuance of common stock, net of offering costs / at-the market offerings     $ 30,613 $ 8,592   74,908,585 74,947,790 74,947,790
Issuance of common stock, net of offering costs / at-the market offerings (in Shares)   8,591,948              
Fair value of IPR&D acquired, net of Business Combination transaction costs     24,765,831   24,765,831 24,765,831
Fair value of IPR&D acquired, net of Business Combination transaction costs (in Shares)                  
Fair value adjustment of LO2A intellectual property revenue sharing obligation     5,440,863   5,440,863 5,440,863
Fair value adjustment of LO2A intellectual property revenue sharing obligation (in Shares)                  
Issuance of common stock, on conversion of convertible notes     $ 63,627     63,627 63,627
Issuance of common stock, on conversion of convertible notes (in Shares)     6,362,690              
Issuance of common stock, exercise of warrants     $ 116     116 116
Issuance of common stock, exercise of warrants (in Shares)     11,590              
Issuance of common stock, stock based compensation     (30,613) $ 5,540,023 197,778   5,707,188 5,707,188
Issuance of common stock, stock based compensation (in Shares)     212,320              
Issuance of common stock, settlement of convertible note interest     $ 8,691 854,778   863,469 863,469
Issuance of common stock, settlement of convertible note interest (in Shares)     86,959              
Issuance of common stock, conversion of Series A preferred stock (in Shares)   (178)   17,800              
Issuance of RSU's and stock options           13,254,121     13,254,121   13,254,121
Issuance of stock by subsidiary to non-controlling interest           163,039     163,039 204,993 368,032
Other       $ (12,272) 16,690 18,633     23,051   23,051
Other (in Shares)       29,596              
Net loss               (47,263,479) (47,263,479)   (47,263,479)
Other comprehensive income             491,399   491,399   491,399
Non-controlling interest                   (660,191) (660,191)
Balance at Sep. 30, 2021 $ 6,145,659 159,624,116 (850,427) (53,611,944) 111,307,404 (482,264) 110,825,140
Balance (in Shares) at Sep. 30, 2021   69,001,071              
Balance at Jun. 30, 2021   $ 6,058,095 (16,690) 80,638,319 (6,038,270) (51,108,458) 29,532,996 (92,868) 29,440,128
Balance (in Shares) at Jun. 30, 2021 178     49,469,490              
Issuance of common stock, net of offering costs / at-the market offerings   $ 8,592 74,908,585 74,917,177   74,917,177
Issuance of common stock, net of offering costs / at-the market offerings (in Shares)       8,591,948              
Issuance of common stock, on conversion of convertible notes   $ 63,627 63,627 63,627
Issuance of common stock, on conversion of convertible notes (in Shares)       6,362,690              
Issuance of common stock, stock based compensation   $ 2,222 197,778 200,000 200,000
Issuance of common stock, stock based compensation (in Shares)       22,222              
Issuance of common stock, settlement of convertible note interest   $ 8,691 750,206 758,897 758,897
Issuance of common stock, settlement of convertible note interest (in Shares)       86,907              
Issuance of common stock, conversion of Series A preferred stock  
Issuance of common stock, conversion of Series A preferred stock (in Shares) (178)     17,800              
Issuance of RSU's and stock options   2,983,318 2,983,318 2,983,318
Issuance of stock by subsidiary to non-controlling interest   163,039 163,039 204,993 368,032
Other   $ 4,432 16,690 (17,129) 3,993 3,993
Other (in Shares)       4,450,014              
Net loss   (2,503,486) (2,503,486) (2,503,486)
Other comprehensive income   5,187,843 5,187,843 5,187,843
Non-controlling interest   (594,389) (594,389)
Balance at Sep. 30, 2021 $ 6,145,659 $ 159,624,116 $ (850,427) $ (53,611,944) $ 111,307,404 $ (482,264) $ 110,825,140
Balance (in Shares) at Sep. 30, 2021   69,001,071